Abstract
We have compared the binding characteristics of [3H]etorphine, a nonselective mu-, delta-, and kappa-opiate agonist, with those of [3H]Tyr-D-Ala-Gly-MePhe-NH(CH2)2OH ([3H]DAGO), a selective mu-agonist, in rabbit cerebellar and thalamic membranes. We have also examined the ability of various unlabeled opioid ligands to compete with the binding of [3H]etorphine in the two preparations. In cerebellar membranes, [3H]DAGO(Kd = 0.7 nM) labels slightly fewer sites than does [3H]etorphine (Kd = 0.06 nM): 0.18 versus 0.24 pmole/mg of protein. In addition, competition studies indicate that up to 75% of the [3H]etorphine binding sites in this preparation display (a) high apparent affinity for unlabeled DAGO and (b) higher apparent affinity for morphine, the prototypical mu-agonist, than for Tyr-D-Ala-Gly-Phe-D-Leu (DADL), a delta-agonist. Together, these results suggest that the rabbit cerebellum contains a very high proportion (0.7-0.8) of mu-opiate binding sites. In thalamic membranes, [3H]DAGO (Kd = 1.1 nM) labels considerably fewer sites than does [3H]etorphine (Kd = 0.08 nM): 0.09 versus 0.27 pmole/mg of protein. In this preparation, the competition curves of DAGO and of DADL resolve binding of [3H]etorphine into two components. The first component accounts for 40-50% of total binding and reflects the interaction of [3H]etorphine with mu-opiate binding sites. The second component (up to 50% of total binding) is unaffected in the presence of DADL at concentrations (1-10 microM) that rule out binding of [3H]etorphine to mu- and delta-opiate binding sites. It disappears readily in the presence of very low concentrations (Ki less than 1 nM) of benzomorphan opiates (bremazocine, cyclazocine, and ethylketocyclazocine) yet it is relatively insensitive to inhibition by mu- and delta-agonists. This second component may therefore reflect [3H]etorphine's interaction with a kappa-opiate binding site. The kappa-opiate binding site is assayed for as that site which binds [3H]etorphine (0.5 nM) in the presence of either DADL (2 microM) or 10 microM of another enkephalin: Tyr-D-Ser-Gly-Phe-Leu-Thr. We find that, in the rabbit central nervous system, the thalamus, followed by frontal cortex and caudate nucleus, shows the highest content of kappa-opiate binding sites.
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|